140 related articles for article (PubMed ID: 7869779)
1. [Cost-effectiveness of the methods of smoking cessation].
Plans P; Navas E; Tarín A; Rodríguez G; Galí N; Gayta R; Taberner JL; Salleras L
Med Clin (Barc); 1995 Jan; 104(2):49-54. PubMed ID: 7869779
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of the nicotine transdermal patch for smoking cessation.
Wasley MA; McNagny SE; Phillips VL; Ahluwalia JS
Prev Med; 1997; 26(2):264-70. PubMed ID: 9085397
[TBL] [Abstract][Full Text] [Related]
3. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
4. Nicotine patches and uninsured quitline callers. A randomized trial of two versus eight weeks.
McAfee TA; Bush T; Deprey TM; Mahoney LD; Zbikowski SM; Fellows JL; McClure JB
Am J Prev Med; 2008 Aug; 35(2):103-10. PubMed ID: 18617079
[TBL] [Abstract][Full Text] [Related]
5. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
7. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
Nielsen K; Fiore MC
Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.
Croghan IT; Offord KP; Evans RW; Schmidt S; Gomez-Dahl LC; Schroeder DR; Patten CA; Hurt RD
Mayo Clin Proc; 1997 Oct; 72(10):917-24. PubMed ID: 9379693
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression.
Barnett PG; Wong W; Hall S
Addiction; 2008 May; 103(5):834-40. PubMed ID: 18412763
[TBL] [Abstract][Full Text] [Related]
11. Should smoking cessation cost a packet? A pilot randomized controlled trial of the cost-effectiveness of distributing nicotine therapy free of charge.
Dey P; Foy R; Woodman M; Fullard B; Gibbs A
Br J Gen Pract; 1999 Feb; 49(439):127-8. PubMed ID: 10326267
[TBL] [Abstract][Full Text] [Related]
12. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial.
Yudkin PL; Jones L; Lancaster T; Fowler GH
Br J Gen Pract; 1996 Mar; 46(404):145-8. PubMed ID: 8731618
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of a family physician delivered smoking cessation program.
Buck DJ; Richmond RL; Mendelsohn CP
Prev Med; 2000 Dec; 31(6):641-8. PubMed ID: 11133329
[TBL] [Abstract][Full Text] [Related]
14. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.
Daughton DM; Fortmann SP; Glover ED; Hatsukami DK; Heatley SA; Lichtenstein E; Repsher L; Millatmal T; Killen JD; Nowak RT; Ullrich F; Patil KD; Rennard SI
Prev Med; 1999 Feb; 28(2):113-8. PubMed ID: 10048102
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
Bolin K; Wilson K; Benhaddi H; de Nigris E; Marbaix S; Mork AC; Aubin HJ
Eur J Public Health; 2009 Dec; 19(6):650-4. PubMed ID: 19491286
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the nicotine patch.
Stevermer J
J Fam Pract; 1996 Aug; 43(2):125-6. PubMed ID: 8708620
[No Abstract] [Full Text] [Related]
17. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program.
Alberg AJ; Stashefsky Margalit R; Burke A; Rasch KA; Stewart N; Kline JA; Ernst PA; Avey A; Hoffman SC
Addict Behav; 2004 Dec; 29(9):1763-78. PubMed ID: 15530720
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
[TBL] [Abstract][Full Text] [Related]
19. The benefits of switching smoking cessation drugs to over-the-counter status.
Keeler TE; Hu TW; Keith A; Manning R; Marciniak MD; Ong M; Sung HY
Health Econ; 2002 Jul; 11(5):389-402. PubMed ID: 12112489
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
Thavorn K; Chaiyakunapruk N
Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
